CYP17A1 and prostate carcinoma: Abiraterone is a 17α−hydroxylase/C17, 20−lyase (CYP17) inhibitor that has been used in patients with prostate cancer after ADT, which was conjugated with NIR fluorescent dye IR780 for prostate cancer imaging and therapy (132).